Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 5 | 2024 | 2771 | 1.000 |
Why?
|
| Zona Pellucida Glycoproteins | 1 | 2025 | 9 | 0.940 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2025 | 898 | 0.880 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 277 | 0.860 |
Why?
|
| T-Lymphocytes | 10 | 2022 | 1772 | 0.810 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 11 | 0.750 |
Why?
|
| Oncolytic Virotherapy | 4 | 2021 | 89 | 0.740 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 51 | 0.710 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 145 | 0.710 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 40 | 0.710 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2024 | 503 | 0.680 |
Why?
|
| Caspase 9 | 4 | 2015 | 76 | 0.660 |
Why?
|
| Adenoviridae | 4 | 2021 | 607 | 0.650 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 562 | 0.580 |
Why?
|
| Immunotherapy | 5 | 2024 | 750 | 0.550 |
Why?
|
| Genetic Therapy | 3 | 2021 | 738 | 0.540 |
Why?
|
| Genetic Vectors | 5 | 2021 | 967 | 0.500 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2025 | 1013 | 0.490 |
Why?
|
| Gene Transfer Techniques | 2 | 2015 | 362 | 0.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 377 | 0.440 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 203 | 0.430 |
Why?
|
| Oncolytic Viruses | 3 | 2021 | 76 | 0.390 |
Why?
|
| Cell Line, Tumor | 12 | 2025 | 3800 | 0.390 |
Why?
|
| Lymphocyte Transfusion | 1 | 2012 | 58 | 0.380 |
Why?
|
| Neoplasms | 3 | 2024 | 3035 | 0.380 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 406 | 0.360 |
Why?
|
| Apoptosis | 4 | 2021 | 1945 | 0.350 |
Why?
|
| Genes, Transgenic, Suicide | 3 | 2015 | 48 | 0.350 |
Why?
|
| Leukemia | 2 | 2011 | 377 | 0.330 |
Why?
|
| Interleukin-15 | 1 | 2010 | 96 | 0.310 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 1783 | 0.310 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 294 | 0.310 |
Why?
|
| Antigens, CD19 | 1 | 2010 | 181 | 0.300 |
Why?
|
| Antigen Presentation | 2 | 2024 | 117 | 0.290 |
Why?
|
| Disease Models, Animal | 5 | 2025 | 4802 | 0.270 |
Why?
|
| Lymphoma | 1 | 2010 | 334 | 0.260 |
Why?
|
| Mice | 13 | 2025 | 19045 | 0.250 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 695 | 0.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 1187 | 0.240 |
Why?
|
| Animals | 16 | 2025 | 36521 | 0.230 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 45 | 0.230 |
Why?
|
| Mice, SCID | 7 | 2021 | 615 | 0.230 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 30 | 0.220 |
Why?
|
| Genetic Engineering | 2 | 2018 | 165 | 0.210 |
Why?
|
| Enzyme Activation | 2 | 2015 | 651 | 0.210 |
Why?
|
| Peptides | 2 | 2024 | 864 | 0.210 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 82 | 0.210 |
Why?
|
| Humans | 24 | 2025 | 134196 | 0.200 |
Why?
|
| Proteogenomics | 1 | 2024 | 110 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1066 | 0.190 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2011 | 519 | 0.190 |
Why?
|
| Gene Expression | 3 | 2015 | 1622 | 0.180 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2021 | 86 | 0.180 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 29 | 0.180 |
Why?
|
| Mastectomy | 1 | 2021 | 82 | 0.180 |
Why?
|
| Helper Viruses | 1 | 2021 | 46 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 1854 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1312 | 0.170 |
Why?
|
| Interleukin-12 | 1 | 2021 | 122 | 0.170 |
Why?
|
| Radiotherapy | 1 | 2021 | 148 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 51 | 0.170 |
Why?
|
| Female | 9 | 2025 | 72037 | 0.160 |
Why?
|
| Dependovirus | 1 | 2021 | 153 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 972 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1144 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 572 | 0.140 |
Why?
|
| Genes, Reporter | 2 | 2015 | 399 | 0.140 |
Why?
|
| Transgenes | 2 | 2015 | 346 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1391 | 0.130 |
Why?
|
| Glioma | 1 | 2021 | 535 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2021 | 271 | 0.120 |
Why?
|
| Fibrin | 1 | 2016 | 65 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2016 | 153 | 0.120 |
Why?
|
| Injections, Intralesional | 1 | 2015 | 49 | 0.120 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2015 | 20 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 700 | 0.120 |
Why?
|
| Glucuronidase | 1 | 2015 | 32 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 190 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2014 | 48 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 805 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1316 | 0.110 |
Why?
|
| Age Factors | 1 | 2021 | 2997 | 0.110 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 296 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 257 | 0.110 |
Why?
|
| Pyrazines | 1 | 2014 | 73 | 0.110 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2013 | 29 | 0.110 |
Why?
|
| Mutation | 2 | 2024 | 6350 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 232 | 0.100 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 240 | 0.100 |
Why?
|
| Neuroblastoma | 2 | 2014 | 551 | 0.090 |
Why?
|
| Virus Replication | 1 | 2015 | 636 | 0.090 |
Why?
|
| Receptors, IgE | 1 | 2011 | 11 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1406 | 0.090 |
Why?
|
| Coculture Techniques | 3 | 2021 | 246 | 0.090 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2011 | 56 | 0.090 |
Why?
|
| Time Factors | 1 | 2021 | 6595 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 653 | 0.080 |
Why?
|
| Models, Biological | 1 | 2016 | 1538 | 0.080 |
Why?
|
| CD28 Antigens | 1 | 2010 | 81 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 7239 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 177 | 0.080 |
Why?
|
| Immunophenotyping | 1 | 2010 | 344 | 0.080 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2009 | 24 | 0.080 |
Why?
|
| Interleukin-7 | 1 | 2009 | 50 | 0.080 |
Why?
|
| Gangliosides | 1 | 2009 | 73 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 352 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 103 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 318 | 0.070 |
Why?
|
| Melanoma | 2 | 2013 | 969 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1621 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 399 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 677 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 179 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2021 | 17579 | 0.050 |
Why?
|
| Aged | 1 | 2021 | 21805 | 0.050 |
Why?
|
| Cell Line | 3 | 2015 | 2863 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 407 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 49 | 0.040 |
Why?
|
| Middle Aged | 1 | 2021 | 29414 | 0.040 |
Why?
|
| Viral Tropism | 1 | 2021 | 53 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 855 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 308 | 0.040 |
Why?
|
| Adult | 1 | 2021 | 31948 | 0.040 |
Why?
|
| Proteomics | 1 | 2024 | 604 | 0.040 |
Why?
|
| HLA-A2 Antigen | 2 | 2011 | 27 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 129 | 0.040 |
Why?
|
| HLA-A Antigens | 2 | 2011 | 34 | 0.040 |
Why?
|
| K562 Cells | 2 | 2011 | 100 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 2011 | 245 | 0.040 |
Why?
|
| Cytokines | 2 | 2014 | 1397 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 29 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2015 | 2915 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 108 | 0.030 |
Why?
|
| Gene Order | 1 | 2015 | 82 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 86 | 0.030 |
Why?
|
| Luciferases, Firefly | 1 | 2014 | 13 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 11 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2015 | 94 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 60 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 233 | 0.030 |
Why?
|
| Dimerization | 1 | 2014 | 153 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 71 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 233 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2016 | 314 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 319 | 0.030 |
Why?
|
| Teratoma | 1 | 2015 | 131 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 2013 | 34 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 249 | 0.030 |
Why?
|
| Heparin | 1 | 2015 | 230 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 399 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 403 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2014 | 912 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 93 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 2137 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 367 | 0.020 |
Why?
|
| Organoids | 1 | 2016 | 300 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 824 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 890 | 0.020 |
Why?
|
| Mesothelioma | 1 | 2013 | 93 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1735 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 920 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1434 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 61 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 795 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 130 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3180 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2562 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 146 | 0.020 |
Why?
|
| Antibodies | 1 | 2009 | 375 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 542 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 703 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2008 | 133 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 867 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 2044 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2011 | 832 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 745 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2793 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2008 | 536 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4610 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1308 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 4012 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 2178 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3876 | 0.010 |
Why?
|
| Male | 2 | 2015 | 66197 | 0.010 |
Why?
|